Filing summary
Important identity discrepancy: The request identifies ARS Pharmaceuticals, Inc., but the supplied filing is Silverback Therapeutics, Inc. (Nasdaq: SBTX), Form 10-Q for the quarter ended June 30, 2021. This summary reflects the supplied filing, not ARS Pharmaceuticals.
Business context and reporting period
Silverback is a clinical-stage biopharmaceutical company developing tissue-targeted therapeutics using its ImmunoTAC platform. Its lead candidate, SBT6050, was in a Phase 1/1b trial; SBT6290 and SBT8230 were in preclinical development. The financial statements are unaudited and cover the three and six months ended June 30, 2021, with comparable 2020 periods.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | No revenue | No revenue | No revenue | No revenue |
| Research and development expense | $17.7 million | $5.1 million | $30.0 million | $9.5 million |
| General and administrative expense | $6.8 million | $1.3 million | $13.4 million | $2.2 million |
| Net loss | $24.5 million | $6.5 million | $43.4 million | $11.7 million |
| Net loss per share | $0.70 | $9.65 | $1.25 | $17.54 |
At June 30, 2021, cash and cash equivalents were $359.7 million, restricted cash was $0.35 million, and total assets were $367.0 million. Total liabilities were $17.3 million, including $2.7 million of lease liabilities; the term loan was fully repaid on May 1, 2021. Operating cash use was $26.3 million for the first half, versus $13.1 million a year earlier; investing cash use was $0.7 million and financing cash provided was $0.2 million. No operating margin is meaningful because the company had no revenue and incurred operating losses.
Material changes versus prior comparable periods
- Q2 operating expenses rose 279% to $24.5 million; first-half expenses rose 271% to $43.4 million. Increased R&D reflected spending on SBT6050 and preclinical programs, while G&A growth reflected headcount, stock compensation, and public-company costs.
- First-half net loss increased to $43.4 million from $11.7 million. Stock-based compensation was $9.0 million for the first half, compared with $0.2 million a year earlier.
- Cash and cash equivalents declined by $26.9 million from December 31, 2020. The company reported $255.3 million in net IPO proceeds in December 2020; it said approximately $18.0 million of those proceeds had been used through June 30, 2021.
Outlook, commentary, risks and unusual items
- Management expected significant operating losses to continue and R&D and G&A expenses to increase as programs advance and the company expands operations.
- The filing gives differing runway statements: the financial-statement note says available cash is sufficient for anticipated requirements for at least 12 months after issuance; MD&A estimates funding for at least 24 months from June 30, 2021. Management also says the cash is not expected to fund candidates through regulatory approval and commercialization, so additional capital will be needed.
- Management anticipated an interim SBT6050 clinical update in Q3 2021 and an IND submission for SBT6290 in Q4 2021. In July 2021, the company announced a Regeneron clinical supply agreement to evaluate SBT6050 with Libtayo in tumor-specific expansion cohorts.
- Material risks include clinical efficacy and safety uncertainty, possible immune-related adverse events including anaphylaxis observed in animal models after repeat intravenous dosing, trial enrollment and COVID-19 disruption, reliance on third-party manufacturers, companion diagnostic requirements, intellectual-property disputes, and future financing and dilution risk.
- A sublease for additional office space was entered into July 1, 2021, with a two-year term and annual minimum rent of approximately $0.3 million. The filing reports no material legal proceedings and no material changes to contractual obligations outside the ordinary course.
Investor verification priorities
- Confirm the intended issuer: the provided document is Silverback Therapeutics, not ARS Pharmaceuticals.
- Reconcile the filing’s 12-month liquidity statement with the MD&A’s 24-month estimate and review the assumptions behind the runway.
- Check subsequent SBT6050 clinical data, safety findings, enrollment progress, and the status of the planned SBT6290 IND submission.
- Track cash burn, expansion of operating expenses, and financing needs, including potential dilution or licensing trade-offs.
- Assess manufacturing and supply-chain dependencies, COVID-19 effects, and intellectual-property risks disclosed in the filing.